as declared in usatoday
Zika vaccine waits on Congress
Zika vaccine waits on Congress
Skip Ad Ad Loading... x Embed x Share Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, discusses prospects for a Zika vaccine with USA TODAY medical reporter Liz Szabo.Rene AlstonVirus is devastating to the small number of people getting infected during pregnancyAnthony Fauci, director of the National Institute of Allergy and Infectious Diseases, meets with the USA TODAY Editorial Board on Aug. 29, 2016.(Photo: Jasper Colt, USAT)Congress returns to Washington this week and is expected to take up the Obama administration's urgent request for more money to fight the Zika virus.
moreover from belfasttelegraph
Zika vaccine research firm attracts private funding offers after clinching grant
Zika vaccine research firm attracts private funding offers after clinching grant
Private investors are queueing up to fund a small British pharmaceutical company that holds promise of developing the world's first Zika vaccine.Excivion seeks private backers to keep research going into the Zika virusPrivate investors are queueing up to fund a small British pharmaceutical company that holds promise of developing the world's first Zika vaccine.Cambridge-based firm Excivion has gained attention since clinching a Government grant worth £500,000 that will help jump-start vaccine development for the mosquito-borne virus.
furthermore pharmacist
HHS accelerates development of mRNA-based Zika vaccine
HHS accelerates development of mRNA-based Zika vaccine
HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded $8.2 million to Moderna Therapeutics to help further development of a novel vaccine against the Zika virus.Under the initial 4-year agreement, ASPR's Biomedical Advanced Research and Development Authority (BARDA) will support a Phase I clinical trial, toxicology studies, vaccine formulation, and manufacturing.The agreement could be extended up to a total of 5 years and a total of $125.5 million to support Phase II and III clinical trials and large-scale manufacturing.
besides enterpriseinnovation
US gov't funds Takeda's Zika vaccine initiative
US gov't funds Takeda's Zika vaccine initiative
The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services, is funding Takeda Pharmaceutical Company's Vaccine Business Unit to develop a vaccine for the Zika virus.Initial funding amounts to $19.8 million to cover the development through Phase 1, with potential additional funding of up to $312 million if ASPR/BARDA exercises all options to take the vaccine through Phase 3 trials and filing of the Biologics License Application (BLA) in the US.Under the agreement, Takeda will develop an inactivated, adjuvanted, whole Zika virus vaccine.
not to mention healthcareitnews
HHS puts Zika vaccine on fast track
HHS puts Zika vaccine on fast track
The Department of Health and Human Services has signed an $8.2 million contract with Cambridge, Mass.-based Moderna Therapeutics to speed what it calls a "novel vaccine" to stop the Zika virus.The funding of Moderna's work comes just days after HHS announced that it would give the Takeda Group in Japan $20 million to accelerate its work developing a Zika vaccine.Takeda's funding goes toward enabling it to prepare for a new drug application and, if all goes well, begin clinical trials as early as next year, while Moderna's focus is on using messenger RNA technology.
No comments:
Post a Comment